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Section A 
Short Answer Questions 
Total No of Marks for this section:  100 
This section should be answered in the Answer Booklet provided. 
Marks for each question are indicated.  Suggested Time allocation for Section A:  180 mins 
___________________________ 
 
 Question 1. Drug development process and methods 
(a) As chief scientific officer of a medium sized biopharma company specialising in oncology, 
you have been asked for you opinion on whether your company should buy the intellectual 
property relating to a new cancer chemotherapeutic from a university start-up. The project is 
targeting what is believed to be a novel mechanism for disrupting mitosis. The project has 
progressed to the stage of having several hits in a biophysical screening campaign.  
What information would you expect the start-up to provide as part of the IP? Produce an 
annotated schematic that you could use as part of your briefing to the company board 
explaining the benefits and risks associated with taking on this project. Assume that the 
annotations need to be sufficient for the schematic to be understood without you being 
present to explain it. 
(Marks 10) 
(b) Tropical diseases affect more than 1 billion people, mostly in developing regions of the 
world.  
i.  Give 2 examples of tropical diseases.  
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Question 2. Metabolomics and natural regulators 
(a) Natural regulators are common starting points for new drugs. Explain, including diagrams 
and/or examples, why many natural regulators, particularly neurotransmitters and peptide 
hormones are not good candidates for direct use as pharmaceuticals and thus require the 
application of medicinal chemistry to turn them into marketable drugs. Factors you should 
consider are: - Stability - Structural rigidity - Lipophilicity - Polarity - Unsuitable functional groups 
 
(Marks 10) 
(b) In one sentence define the following terms: 
i. Metabolomics 
ii. Lipidomics 
iii. Metabolic footprinting 
 (Marks 3) 
(c) Using a flowchart, outline the key steps in the metabolomics analysis (profiling) of tissue 
extracts taken from a study of 50 individuals. Include details on sample preparation and the 
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Question 3. Hit-to-lead chemistry 
(a) Define: 
i. Homologous series 
ii. Pro-drug 
iii. Log P 
iv. The “rule of five” (2 marks) 
(Marks 5) 
(b) Describe the chemical and structural and potential binding effects making changes to the 
size, bonding and atoms in the central ring (carbons numbered 9 and 10) of the following 
compound (anthracene): 
 
Factors to consider are: - non-aromatic carbons - change to seven membered ring - introduction of heteroatoms at positions 9 and 10 - combination of heteroatoms and seven membered ring 
(Marks 8) 
(c) The compound below was discovered to be an effective enzyme inhibitor. What 
modifications would you make to this compound in order to discover the pharmacophore and 




THIS EXAMINATION PAPER AND SUPPLIED MATERIALS ARE NOT PERMITTED TO BE REMOVED FROM 
ANY EXAMINATION VENUE IN ANY CIRCUMSTANCE. THIS EXAMINATION IS PRINTED DOUBLE-SIDED. 
 
Semester 1, 2016 FINAL EXAMINATION 
 PHA212 – Medicinal Chemistry 
Page 6 of 7 
Question 4. Screening and structure based design 
(a) Define: 
i. Allosteric inhibitor 
ii. Antagonist 
iii. Pharmacophore 
iv. Phenotypic screening 
(Marks 4) 
(b)  
i. In the diagram below, what type of reaction is occurring?  
Using the concept of bioisosteres: 
ii. Design a reversible competitive inhibitor for the following reaction. Explain your reasoning 
iii. Design a multi-substrate analogue inhibitor. Explain your reasoning 
  
(Marks 7) 
(c) Surface plasmon resonance, isothermal titration calorimetry and nuclear magnetic 
resonance are all common biophysical methods for screening compound libraries for binding to 
isolated target molecules.  
In terms of structural information gathered, binding kinetics and thermodynamics, explain the 
relative advantages of these three techniques for screening a pharmaceutical compound 
library for binding to a soluble protein target.  
(Marks 9) 
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Question 5. Drug-target interaction chemistry 
(a) Explain and give examples of the following types of chemical interaction: 
i. Van der Waals forces 
ii. Dipole-ion interaction 
iii. Hydrogen bonding 
(Marks 6) 
(b) Draw, annotate and explain the organic chemical reaction mechanism for the interaction 
between alkylating cytotoxic cancer chemotherapeutic cyclophosphamide (structure below) 
and DNA 
                                                                
(Marks 6) 
(c) Beta-lactams (e.g. amoxicillin) and glycopeptide antibiotics (e.g. vancomycin) both inhibit 
the enzyme responsible for building bacterial cell walls (D-D-transpepidases).  
i. Explain the chemical reasons (including mechanisms if needed) that amoxicillin is 
orally bioavailable while vancomycin is not 
ii. Explain the chemical reasons (including mechanisms if needed) that amoxicillin is 
often given in conjunction with clavulanic acid but is not used in vancomycin 
treatment 
  
(Marks 8) 
 
 
